# Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06958328/  
OnCo record `nct06958328` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of capecitabine, fluorouracil (5-FU), gemcitabine, irinotecan (and liposomal irinotecan) and other drugs in pancreatic cancer, run by NRG Oncology, now recruiting.

## Summary

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT06958328 by NRG Oncology, with a registry enrolment figure of 356 participants, started 2025-08-21 and due to reach its primary completion in 2030-10-21. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Capecitabine; Computed Tomography; Dose-escalated Radiation Therapy; Fluorouracil; Gemcitabine; Irinotecan Hydrochloride; Irinotecan Sucrosofate; Leucovorin Calcium; Magnetic Resonance Imaging; Nab-paclitaxel; Observation Activity; Oxaliplatin; Positron Emission Tomography; Questionnaire Administration; Radiation Therapy; Tumor Treating Fields Therapy. Conditions listed: Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8. Primary outcome: Overall survival (OS). Pancreatic eligibility wording from the registry: "* Pathologically (histologically or cytologically) proven diagnosis of pancreatic ductal adenocarcinoma". Sites: Canada, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: LAP100
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06958328
- Phase: 3
- Setting: A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
- Sponsor: NRG Oncology
- Enrolled: 356

## Sources

- ClinicalTrials.gov NCT06958328: https://clinicaltrials.gov/study/NCT06958328

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/), [Tumour treating fields (TTFields)](https://onco.cc/technologies/ttfields/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06958328.json